| Drug Name |
Sorafenib |
| Drug ID |
BADD_D02058 |
| Description |
Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials.
Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway. |
| Indications and Usage |
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. |
| Marketing Status |
Prescription |
| ATC Code |
L01EX02 |
| DrugBank ID |
DB00398
|
| KEGG ID |
D08524
|
| MeSH ID |
D000077157
|
| PubChem ID |
216239
|
| TTD Drug ID |
D0W5HK
|
| NDC Product Code |
0378-1201; 68554-0073; 12527-8488; 63850-8051; 47049-848; 50419-488; 43744-545 |
| Synonyms |
Sorafenib | Nexavar | BAY 43-9006 | BAY 43 9006 | BAY 439006 | Sorafenib N-Oxide | Sorafenib N Oxide | BAY-673472 | BAY 673472 | BAY 545-9085 | BAY 545 9085 | BAY 5459085 | BAY-545-9085 | BAY5459085 | Sorafenib Tosylate | 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate |
